1.285
price down icon5.17%   -0.07
after-market After Hours: 1.32 0.035 +2.72%
loading
Zentalis Pharmaceuticals Inc stock is traded at $1.285, with a volume of 643.25K. It is down -5.17% in the last 24 hours and down -33.07% over the past month.
See More
Previous Close:
$1.355
Open:
$1.26
24h Volume:
643.25K
Relative Volume:
0.38
Market Cap:
$92.28M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.283
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
-28.21%
1M Performance:
-33.07%
6M Performance:
-59.84%
1Y Performance:
-91.77%
1-Day Range:
Value
$1.21
$1.30
1-Week Range:
Value
$1.21
$1.81
52-Week Range:
Value
$1.21
$16.21

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name
Name
Zentalis Pharmaceuticals Inc
Name
Phone
(858) 263-4333
Name
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Name
Employee
0
Name
Twitter
@ZentalisP
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
ZNTL's Discussions on Twitter

Compare ZNTL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ZNTL
Zentalis Pharmaceuticals Inc
1.285 92.28M 0 -292.19M -208.41M -4.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-12-24 Upgrade Wedbush Underperform → Neutral
Jun-20-24 Downgrade UBS Buy → Neutral
Jun-18-24 Downgrade Jefferies Buy → Hold
Jun-18-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-18-24 Downgrade Wedbush Neutral → Underperform
Jun-18-24 Downgrade Wells Fargo Overweight → Equal Weight
Nov-08-23 Downgrade Wedbush Outperform → Neutral
Nov-07-23 Downgrade Leerink Partners Outperform → Market Perform
Jul-12-22 Initiated Cowen Outperform
Apr-06-22 Initiated Wells Fargo Overweight
Oct-07-21 Resumed Jefferies Buy
Sep-30-21 Initiated Stifel Buy
Sep-29-21 Initiated Oppenheimer Outperform
May-21-21 Initiated UBS Buy
Jan-20-21 Initiated Wedbush Outperform
Sep-29-20 Initiated Cantor Fitzgerald Overweight
Aug-27-20 Initiated H.C. Wainwright Buy
Apr-28-20 Initiated Guggenheim Buy
Apr-28-20 Initiated Jefferies Buy
Apr-28-20 Initiated Morgan Stanley Overweight
Apr-28-20 Initiated SVB Leerink Outperform
View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

pulisher
02:39 AM

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages - Defense World

02:39 AM
pulisher
Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Zentalis Strengthens Team with $194,600 in Equity Incentives - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Sells 10,375 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals Reports Progress and Financials - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Stifel maintains Buy on Zentalis stock with $9 target By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc Reports Annual EPS of -$2.33, Excee - GuruFocus

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Breakthrough: 35% Response Rate in Ovarian Cancer Trial Wins FDA Fast Track - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Zentalis Pharmaceuticals to Present Multiple Posters at the - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView

Mar 25, 2025
pulisher
Mar 21, 2025

Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 20, 2025

Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN

Mar 20, 2025
pulisher
Mar 19, 2025

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright - The AM Reporter

Mar 19, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains $10 target on Zentalis stock By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Zentalis Highlights Promising Azenosertib Data at SGO 2025 - TipRanks

Mar 17, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at - GlobeNewswire

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - MarketScreener

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC - Nasdaq

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - TradingView

Mar 15, 2025
pulisher
Mar 15, 2025

Breakthrough: Zentalis Drug Achieves 35% Response Rate Against Hard-to-Treat Ovarian Cancer - Stock Titan

Mar 15, 2025
pulisher
Mar 11, 2025

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Has Been Trading Down. What Are The Prospects For The Future? - stocksregister.com

Mar 11, 2025
pulisher
Mar 09, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 03, 2025

How Zentalis Is Attracting Talent: Inside Their Latest Employee Compensation Package - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Zentalis Pharmaceuticals Announces Multiple Data - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Yahoo Finance

Mar 03, 2025
pulisher
Feb 27, 2025

A company insider recently bought 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL]. Should You Buy? - Knox Daily

Feb 27, 2025
pulisher
Feb 25, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc.ZNTL - PR Newswire

Feb 25, 2025
pulisher
Feb 24, 2025

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can Zentalis' Novel Cancer Drug Pipeline Impress at Two Elite Healthcare Conferences? - StockTitan

Feb 24, 2025
pulisher
Feb 23, 2025

Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Tuesday - The AM Reporter

Feb 23, 2025
pulisher
Feb 22, 2025

Zentalis stock price target cut to $10 by H.C. Wainwright - MSN

Feb 22, 2025
pulisher
Feb 22, 2025

Zentalis pharmaceuticals officer sells $24,590 in stock - MSN

Feb 22, 2025
pulisher
Feb 21, 2025

Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently - Yahoo Finance

Feb 21, 2025
pulisher
Feb 20, 2025

Savant Capital LLC Acquires New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Feb 20, 2025
pulisher
Feb 16, 2025

Zentalis stock plunges to 52-week low, hits $2.16 - MSN

Feb 16, 2025

Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Cap:     |  Volume (24h):